Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Aldrich Signs Exclusive Agreement with IsoSciences to Distribute Isotopically Labeled Bioactive Compounds

Published: Friday, September 12, 2008
Last Updated: Friday, September 12, 2008
Bookmark and Share
Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement for metabolic research.

Sigma-Aldrich has announced that it has entered into an exclusive agreement with IsoSciences, LLC, to distribute isotopically labeled bioactive compounds and their metabolites through its Aldrich division.

IsoSciences, a leading stable isotope company, provides a wide array of biological compounds and custom synthesis products. Aldrich, provider of ISOTEC(R) Stable Isotopes, is a leader in manufacturing and providing stable isotope products for biomolecular NMR, proteomics, metabolic and MRI research.

Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement. These products include deuterated, 13C and 15N labeled vitamins, steroids, and other bioactive compounds used in metabolic research.

Nutrition and metabolic research investigates the relationships among diet, health and diseases by nutrient interactions with various metabolic pathways, bioavailability and nutrient analysis. These stable isotope products will be an addition to the extensive list of unlabeled bioactive compounds provided by Sigma-Aldrich.

"A new partnership with IsoSciences will allow Sigma-Aldrich to provide new stable isotope product lines to support our customers' research," said Dr. C.T. Tan, ISOTEC Stable Isotope's R&D Manager. "This collaboration offers a new range of labeled bioactive compounds for our ever expanding customer base."

"We have invested heavily in synthesizing difficult-to-prepare, yet vitally needed, isotopically labeled standards," said David Saunders, President of IsoSciences, LLC.

IsoSciences' CEO Dr. Scott W. Landvatter added, "Our partnership with Sigma-Aldrich will allow us the widest possible distribution of our unique stable isotope labeled compounds to scientists worldwide."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SAFC Completes Manufacturing Expansion in St. Louis
Expansion to support commercial-scale antibody drug conjugate (ADC) manufacturing.
Saturday, May 16, 2015
SAFC Expands Carlsbad, Calif. Facility
Expansion to support commercial-scale gene therapy production, testing and filling.
Saturday, May 16, 2015
Sigma-Aldrich Expands in Singapore
New State-of-the-Art Technical Center, cGMP Distribution Center and Headquarters enhances ability to support customers in the region.
Monday, April 20, 2015
Sigma-Aldrich & Roche Enter Exclusive Distribution Agreement
Provides researchers with global access to Roche biochemical reagents product portfolio.
Thursday, March 19, 2015
Sigma and Czech Center for Phenogenomics Collaborate
Sigma-Aldrich® and the Institute of Molecular Genetics, Czech Center for Phenogenomics, establish CRISPR core lab collaboration.
Friday, January 30, 2015
SAFC’s Dry Powder Media Manufacturing Facility in Irvine, Scotland
Officially opens following extensive validation process.
Friday, January 23, 2015
Sigma-Aldrich Licenses Foundational CRISPR Patents from Broad Institute
Company is able to make, use and distribute the advanced gene editing tools for numerous research applications.
Tuesday, December 09, 2014
Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.
Friday, October 19, 2012
Sigma-Aldrich to Acquire BioReliance
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.
Tuesday, January 10, 2012
Biotech firm inks deal with Sigma-Aldrich
Henrietta-based biotechnology company Diffinity Genomics Inc. has inked a non-exclusive global distribution deal with Sigma-Aldrich Co. LLC, the local company said.
Wednesday, November 30, 2011
Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Materials
Materials show promise as high energy, low pressure hydrogen source.
Monday, July 25, 2011
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins Involved in Cancer and Stem Cell Biology
Domainex Ltd., have announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics.
Monday, November 15, 2010
Sigma® Life Science to Supply Oligonucleotides to Research Councils UK
A three-year contract with RCUK Shared Services Centre Limited to be a preferred supplier for synthetic oligonucleotides.
Monday, September 20, 2010
Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.
Monday, August 09, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!